Arcoma AB (OSTO:ARCOMA) Research & Development: kr0.0 Mil (TTM As of Mar. 2026)


OSTO:ARCOMA Arcoma AB OSTO:ARCOMA
75 GF Score
Price kr8.80
GF Value kr7.85
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Arcoma AB Research & Development?

Arcoma AB OSTO:ARCOMA +3.53% 75 Research & Development is kr0.0 Mil as of Mar. 2026. GuruFocus rates OSTO:ARCOMA with a GF Score™ of 75/100 and a GF Value™ of kr7.85 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Arcoma AB's Research & Development for the three months ended in Mar. 2026 was kr0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.0 Mil.

Arcoma AB  (OSTO:ARCOMA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Arcoma AB Research & Development Related Terms

Arcoma AB Research & Development Historical Data

* Premium members only.

The historical data trend for Arcoma AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcoma AB Research & Development Chart

Arcoma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Arcoma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:ARCOMA
75GF Score
Arcoma AB OSTO:ARCOMA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcoma AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr0.0 Mil mean?
Arcoma AB (OSTO:ARCOMA) has a Research & Development of kr0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Arcoma AB and its competitors.
Is Arcoma AB's Research & Development too high?
Arcoma AB's current Research & Development is kr0.0 Mil. Overall, Arcoma AB has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcoma AB's Research & Development compare to ABT and SYK?
Arcoma AB's Research & Development of kr0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Arcoma AB and its competitors. Arcoma AB's current Research & Development is kr0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcoma AB stock overvalued right now?
Based on GuruFocus' analysis, Arcoma AB (OSTO:ARCOMA) is currently considered Modestly Overvalued. The stock's GF Value™ is kr7.85, compared to a current price of kr8.80 — trading 12.1% above its estimated fair value. The current Research & Development is kr0.0 Mil. Arcoma AB's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Arcoma AB (OSTO:ARCOMA), the current Research & Development is kr0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcoma AB (OSTO:ARCOMA) Overvalued in 2026?

Based on GuruFocus' analysis, Arcoma AB stock appears to be overvalued. The current stock price of kr8.80 is trading 12.1% above its estimated GF Value™ of kr7.85. GuruFocus considers Arcoma AB to be Modestly Overvalued.

Key valuation signals for OSTO:ARCOMA:

  • Research & Development: kr0.0 Mil
  • GF Value™: kr7.85 vs. price of kr8.80 (12.1% above fair value)
  • GF Score™: 75/100 with 4 warning signs

No single metric tells the full story. See the OSTO:ARCOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcoma AB Business Description

Address Annavagen 1, Vaxjo, SWE, SE-352 46
Arcoma AB provides digital radiography systems in Sweden. It offers products including wireless flat panel detectors, positioning devices, and precision dr systems.
75GF Score

Get the complete analysis for OSTO:ARCOMA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr8.80
Price
kr7.85
GF Value